Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pulnovo Medical Completes Trial Enrollment for Pulmonary Hypertension Device

publication date: Jun 28, 2021

Pulnovo Medical, a Nanjing medical device company, has completed enrollment in a China trial of its PADN® device, which ablates the sympathetic nerve to treat pulmonary hypertension, a disease that is difficult to diagnose and treat. The device uses a novel multi-electrode ring tip to dispense the radiofrequency for the ablation. The ablation is designed to cause percutaneous pulmonary artery denervation, lowering pulmonary hypertension. The US FDA granted the device breakthrough designation in 2021. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital